J. Sprouse

发表

5-HT1A agonist activity of pindolol: reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100,635.

J. Sprouse, J. Braselton, L. Reynolds, 1998, Annals of the New York Academy of Sciences.

Antagonism of 5‐HT1A receptors uncovers an excitatory effect of SSRIs on 5‐HT neuronal activity, an action probably mediated by 5‐HT7 receptors

B. Westerink, J. D. den Boer, T. Cremers, 2009, Journal of neurochemistry.

2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists.

Anne W. Schmidt, R. Obach, R. Mansbach, 2008, Journal of medicinal chemistry.

Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.

Anne W. Schmidt, F. Tingley, T. Seeger, 2008, Journal of medicinal chemistry.

Innovative therapeutic actions by targeting serotonin 1A receptors selectively

L. Wilkinson, J. Sprouse, 1995 .

Small molecule antagonists of melanopsin-mediated phototransduction

S. Panda, G. E. Pickard, Megumi Hatori, 2013, Nature chemical biology.

Fluoxetine Modulates the Circadian Biological Clock via Phase Advances of Suprachiasmatic Nucleus Neuronal Firing

J. Sprouse, J. Braselton, L. Reynolds, 2006, Biological Psychiatry.

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Anne W. Schmidt, M. Corman, P. Seymour, 1996, Proceedings of the National Academy of Sciences of the United States of America.

332. 5-MeO-DMT Modifies Innate Behaviors and Promotes Structural Neural Plasticity in Mice

C. Pittenger, Pasha A Davoudian, A. Kwan, 2022, Biological Psychiatry.

3,4-methylenedioxymethamphetamine (MDMA)-induced release of endogenous serotonin from the rat dorsal raphe nucleus in vitro: Effects of fluoxetine and tryptophan

R. Roth, G. Aghajanian, C. Bradberry, 1990, Neurochemistry International.

Brain cell signaling abnormalities are detected in blood in a murine model of Fragile X syndrome and corrected by Sigma‐1 receptor agonist Blarcamesine

W. Kaufmann, R. Deacon, D. Klamer, 2022, American journal of medical genetics. Part A.

Chronic treatment with a selective inhibitor of casein kinase I δ/ε yields cumulative phase delays in circadian rhythms

G. E. Pickard, R. Kleiman, Terri A. Swanson, 2010, Psychopharmacology.

NAN-190 potentiates the circadian response to light and speeds re-entrainment to advanced light cycles

M. Harrington, J. Sprouse, E. Kessler, 2008, Neuroscience.

Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

W. Kaufmann, L. Oberman, R. Deacon, 2021, Scientific Reports.

ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome

W. Kaufmann, D. Klamer, T. Hanania, 2019, Pharmacology Biochemistry and Behavior.

Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.

Anne W. Schmidt, H. Wikström, E. S. Vermeulen, 2004, Journal of medicinal chemistry.

Tryptophan pretreatment augmentation of p-chloroamphetamine-induced serotonin and dopamine release and reduction of long-term neurotoxicity.

R. Roth, G. Aghajanian, Rajeshwari Iyer, 1994, Biochemical pharmacology.

Activation of postsynaptic 5‐HT1A receptors by fluoxetine despite the loss of firing‐dependent serotonergic input: Electrophysiological and neurochemical studies

H. Rollema, J. Sprouse, J. Braselton, 2001, Synapse.

(-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists.

G. Aghajanian, J S Sprouse, G K Aghajanian, 1986, European journal of pharmacology.

5-HT1A agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus

J. Sprouse, J. Braselton, L. Reynolds, 2000, Biological Psychiatry.

Plasma levels of free and acid‐labile hydralazine: Effects of multiple dosing and of procainamide

D. Schneck, J. Sprouse, A. Hayes, 1978, Clinical pharmacology and therapeutics.

Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists

G. Aghajanian, J S Sprouse, G K Aghajanian, 1987, Synapse.

Pharmacologic excitability of rat motor nerve endings: the effect of adrenalectomy on neostigmine-induced fasciculations.

J. Sprouse, W. Riker, T. Baker, 1985, The Journal of pharmacology and experimental therapeutics.

Comparison of the Novel Antipsychotic Ziprasidone with Clozapine and Olanzapine: Inhibition of Dorsal Raphe Cell Firing and the Role of 5-HT1A Receptor Activation

S. Zorn, H. Rollema, J. Sprouse, 1999, Neuropsychopharmacology.

An Inhibitor of Casein Kinase Iϵ Induces Phase Delays in Circadian Rhythms under Free-Running and Entrained Conditions

Eric Schaeffer, Robin Kleiman, Katherine Fisher, 2007, Journal of Pharmacology and Experimental Therapeutics.

Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: A comparative study with dorsal raphe neurons

G. Aghajanian, J. S. Sprouse, G. K. Aghajanian, 1988, Neuropharmacology.

Sub-picogram determination of serotonin using HPLC with electrochemical detection for microdialysis studies of serotonin release.

R. Roth, G. Aghajanian, C. Bradberry, 1991, Advances in experimental medicine and biology.

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.

Anne W. Schmidt, S. Zorn, Y. Lu, 2000, Biological psychiatry.

Comparison of the Effects of Sertraline and Its Metabolite Desmethylsertraline on Blockade of Central 5-HT Reuptake In Vivo

J. Heym, H. Rollema, J. Sprouse, 1996, Neuropsychopharmacology.

Inhibition of dorsal raphe cell firing by MDL 73005EF, a novel 5-HT1A receptor ligand.

J. Sprouse, 1991, European journal of pharmacology.

5-HT 1A Partial Agonists as Anxiolytics and Antidepressants

J. Sprouse, 1997 .

Apparent regional differences in 5-HT1A binding may reflect [3H]8-OH-DPAT labeling of serotonin uptake sites

J. Sprouse, D. McCarty, M. W. Dudley, 1993, Brain Research.

Electrophysiology of the Central Serotonin System: Receptor Subtypes and Transducer Mechanisms a

G. Aghajanian, G. Aghajanian, K. Rasmussen, 1990, Annals of the New York Academy of Sciences.

Combined Administration of a 5‐Hydroxytryptamine (5‐HT)1D Antagonist and a 5‐HT Reuptake Inhibitor Synergistically Increases 5‐HT Release in Guinea Pig Hypothalamus In Vivo

H. Rollema, D. Schulz, J. Sprouse, 1996, Journal of neurochemistry.

Do 5-HT1B/1D Autoreceptors Modulate Dorsal Raphe Cell Firing? In Vivo Electrophysiological Studies in Guinea Pigs with GR127935

H. Rollema, J. Sprouse, L. Reynolds, 1997, Neuropharmacology.

The effects of combining serotonin reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm regulation in rodents

C. Sánchez, J. Sprouse, L. Westrich, 2013, Physiology & Behavior.

An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions.

Eric Schaeffer, Robin Kleiman, Katherine Fisher, 2007, The Journal of pharmacology and experimental therapeutics.

5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

Anne W. Schmidt, S. Zorn, H. Rollema, 2000, Biological Psychiatry.

Electrophysiology of Central Serotonin Receptor Subtypes

G. Aghajanian, K. Rasmussen, J. Sprouse, 1988 .

Inhibition of casein kinase I ε/δ produces phase shifts in the circadian rhythms of Cynomolgus monkeys

M. Engwall, Terri A. Swanson, J. Sprouse, 2009, Psychopharmacology.

Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.

Anne W. Schmidt, H. Wikström, E. S. Vermeulen, 2003, Journal of medicinal chemistry.

In vitro microdialysis: a novel technique for stimulated neurotransmitter release measurements

R. Roth, G. Aghajanian, C. Bradberry, 1991, Journal of Neuroscience Methods.

Circadian Rhythm Phenotype of 5-HT₇ Receptor Knockout Mice: 5-HT and 8-OH-DPAT-Induced Phase Advances of SCN Neuronal Firing

J. Stock, J. Mcneish, J. Sprouse, 2005, Journal of biological rhythms.

3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan.

R. Roth, G. Aghajanian, C. Bradberry, 1990, European journal of pharmacology.

8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production

J. Sprouse, J. Braselton, L. Reynolds, 2004, Neuropharmacology.

Pharmacological modulation of circadian rhythms: a new drug target in psychotherapeutics

J. Sprouse, 2004, Expert opinion on therapeutic targets.

Serotonin and the Regulation of Mammalian Circadian Rhythms

P. J. Sollars, J. Sprouse, G. E. Pickard, 2009 .

Circadian rhythm dysregulation in bipolar disorder.

J. Sprouse, L. Westrich, 2010, Current opinion in investigational drugs.

SIGMA-1 RECEPTOR TARGET OCCUPANCY STUDY WITH DYNAMIC PET SCAN ANALYSIS OF ANAVEX®2-73: A CLINICAL CANDIDATE FOR NEURODEGENERATIVE AND NEURODEVELOPMENTAL DISEASES

F. Chin, J. Sprouse, Samantha T. Reyes, 2018, Alzheimer's & Dementia.

Electrophysiology of Brain Serotonin Receptors: Subtype Specificity for Effector Mechanisms

G. Aghajanian, K. Rasmussen, J. Sprouse, 1990 .

MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin.

R. Roth, G. Aghajanian, C. Bradberry, 1989, European journal of pharmacology.

Serotonin‐induced phase advances of SCN neuronal firing in vitro: A possible role for 5‐HT5A receptors?

J. Sprouse, J. Braselton, L. Reynolds, 2004, Synapse.

The effect of hydralazine and other drugs on the kinetics of procainamide acetylation by rat liver and kidney N-acetyltransferase.

R. Shiroff, D. Schneck, J. Sprouse, 1978, The Journal of pharmacology and experimental therapeutics.